Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Saved in:
| Title: | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. |
|---|---|
| Authors: | Shah MH; Ohio State University College of Medicine, Columbus, OH, 43210, USA., Lorigan P; University of Manchester/Christie NHS Foundation Trust, Manchester, M20 4BX, UK., O'Brien ME; Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK., Fossella FV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Moore KN; University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA., Bhatia S; Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA., Kirby M; ImmunoGen, Inc., Waltham, MA, 02451, USA., Woll PJ; Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK. p.j.woll@sheffield.ac.uk. |
| Source: | Investigational new drugs [Invest New Drugs] 2016 Jun; Vol. 34 (3), pp. 290-9. Date of Electronic Publication: 2016 Mar 09. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
